Cimicoxib
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 319629

CAS#: 265114-23-6

Description: Cimicoxib, aslo known as UR-8880, is a non-steroidal anti-inflammatory drug (NSAID) used in veterinary medicine to treat dogs for pain and inflammation associated with osteoarthritis and for the management of pain and inflammation associated with surgery. It acts as a COX-2 inhibitor.

Chemical Structure

img
Cimicoxib
CAS# 265114-23-6
Product data Instruction

Theoretical Analysis

MedKoo Cat#: 319629
Name: Cimicoxib
CAS#: 265114-23-6
Chemical Formula: C16H13ClFN3O3S
Exact Mass: 381.04
Molecular Weight: 381.806
Elemental Analysis: C, 50.33; H, 3.43; Cl, 9.28; F, 4.98; N, 11.01; O, 12.57; S, 8.40

Price and Availability

Size Price Availability Quantity
10mg USD 150 Ready to ship
25mg USD 250 Ready to ship
50mg USD 450 Ready to ship
100mg USD 750 Ready to ship
200mg USD 1350 Ready to ship
500mg USD 2250 Ready to ship
1g USD 3650 Ready to ship
2g USD 4850 2 weeks
5g USD 7950 2 weeks
Bulk inquiry

Synonym: UR-8880; UR8880; UR8880; Cimicoxib; trade name: Cimalgex.

IUPAC/Chemical Name: 4-[4-Chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl]benzenesulfonamide

InChi Key: KYXDNECMRLFQMZ-UHFFFAOYSA-N

InChi Code: InChI=1S/C16H13ClFN3O3S/c1-24-14-7-2-10(8-13(14)18)15-16(17)20-9-21(15)11-3-5-12(6-4-11)25(19,22)23/h2-9H,1H3,(H2,19,22,23)

SMILES Code: O=S(C1=CC=C(N2C(C3=CC=C(OC)C(F)=C3)=C(Cl)N=C2)C=C1)(N)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO, not in water

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target: Cimicoxib that inhibits COX-2 selectively over COX-1 (IC50s = 0.005 and 3.3 μM, respectively).
In vitro activity: N/A
In vivo activity: Quinidine, a specific CYP2D15 inhibitor, is the most potent inhibitor of the metabolism of cimicoxib in canine and feline microsomes. Therefore, CYP2D15 is the main enzyme involved in the in vitro metabolism of cimicoxib in both species, among those tested. To a lower extent, CYP3A12 is also involved in the in vitro metabolism of cimicoxib. Quinidine inhibition of the metabolism of cimicoxib was about 30 times more potent in feline microsomes than in canine microsomes. As these results were obtained by competitive inhibition, the affinity of cimicoxib towards the enzyme was about 30 times lower in feline microsomes compared to canine microsomes. This activity difference may contribute to the slower in vivo elimination of cimicoxib in cats. Reference: Vet J. 2021 Apr;270:105625. https://pubmed.ncbi.nlm.nih.gov/33641805/

Preparing Stock Solutions

The following data is based on the product molecular weight 381.81 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol: N/A
In vitro protocol: N/A
In vivo protocol: 1. Schneider M, Dron F, Cuinet E, Woehrlé F. Comparative pharmacokinetic profile of cimicoxib in dogs and cats after IV administration. Vet J. 2021 Apr;270:105625. doi: 10.1016/j.tvjl.2021.105625. Epub 2021 Feb 1. PMID: 33641805. 2. Di Salvo A, Giorgi M, Lee HK, Vercelli C, Rueca F, Marinucci MT, Rocca GD. Plasma profile of cimicoxib in sheep after oral administration at two different rates. Pol J Vet Sci. 2017 Sep 26;20(3):535-538. doi: 10.1515/pjvs-2017-0065. PMID: 29166275.

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Schneider M, Kuchta A, Dron F, Woehrlé F. Disposition of cimicoxib in plasma and milk of whelping bitches and in their puppies. BMC Vet Res. 2015 Jul 31;11:178. doi: 10.1186/s12917-015-0496-4. PubMed PMID: 26228538; PubMed Central PMCID: PMC4521454.

2: Kropf J, Bennett RC, Self G, Monticelli P, Huuskonen V. Efficacy and safety of cimicoxib in the control of perioperative pain in dogs: a critique. J Small Anim Pract. 2014 Dec;55(12):652-3. doi: 10.1111/jsap.12302_1. PubMed PMID: 25470417.

3: Kim TW, Della Rocca G, Di Salvo A, Ryschanova R, Sgorbini M, Giorgi M. Evaluation of pharmacokinetic and pharmacodynamic properties of cimicoxib in fasted and fed horses. N Z Vet J. 2015 Mar;63(2):92-7. doi: 10.1080/00480169.2014.950355. Epub 2015 Jan 27. PubMed PMID: 25075617.

4: Kim TW, Lebkowska-Wieruszewska B, Owen H, Yun HI, Kowalski CJ, Giorgi M. Pharmacokinetic profiles of the novel COX-2 selective inhibitor cimicoxib in dogs. Vet J. 2014 Apr;200(1):77-81. doi: 10.1016/j.tvjl.2013.12.020. Epub 2013 Dec 31. PubMed PMID: 24461644.

5: Jeunesse EC, Schneider M, Woehrle F, Faucher M, Lefebvre HP, Toutain PL. Pharmacokinetic/pharmacodynamic modeling for the determination of a cimicoxib dosing regimen in the dog. BMC Vet Res. 2013 Dec 11;9:250. doi: 10.1186/1746-6148-9-250. PubMed PMID: 24330630; PubMed Central PMCID: PMC3892053.

6: Grandemange E, Fournel S, Woehrlé F. Efficacy and safety of cimicoxib in the control of perioperative pain in dogs. J Small Anim Pract. 2013 Jun;54(6):304-12. doi: 10.1111/jsap.12082. PubMed PMID: 23710692; PubMed Central PMCID: PMC3743348.

7: Giorgi M, Kim TW, Saba A, Rouini MR, Yun H, Ryschanova R, Owen H. Detection and quantification of cimicoxib, a novel COX-2 inhibitor, in canine plasma by HPLC with spectrofluorimetric detection: development and validation of a new methodology. J Pharm Biomed Anal. 2013 Sep;83:28-33. doi: 10.1016/j.jpba.2013.04.024. Epub 2013 Apr 25. PubMed PMID: 23685411.

8: Almansa C, Bartrolí J, Belloc J, Cavalcanti FL, Ferrando R, Gómez LA, Ramis I, Carceller E, Merlos M, García-Rafanell J. New water-soluble sulfonylphosphoramidic acid derivatives of the COX-2 selective inhibitor cimicoxib. A novel approach to sulfonamide prodrugs. J Med Chem. 2004 Oct 21;47(22):5579-82. PubMed PMID: 15481993.